Group 1 - The core point of the article is that Brother Technology's subsidiary, Zhejiang Brother Pharmaceutical Co., Ltd., has received a drug registration certificate for Iopamidol injection, which is now approved for market sale in China [1][3] - The Iopamidol injection is classified as a Class 4 chemical drug and has been included in the National Medical Insurance Class A directory and the seventh batch of national drug centralized procurement [1][3] - The domestic market size for Iopamidol is projected to be approximately 450 million yuan in 2024, indicating a significant market opportunity for the company [1] Group 2 - On September 22, Brother Technology's stock closed at 7.17 yuan, down 1.92%, with a turnover rate of 13.39% and a trading volume of 939,200 shares, amounting to a transaction value of 675 million yuan [1] - The net outflow of main funds on September 22 was 40.2 million yuan, while retail investors saw a net inflow of 48.0 million yuan [1][3] - The approval of the drug registration certificate is expected to enhance the company's product line in iodine contrast agents and improve its market competitiveness [1]

Group 1 - Global Printing announced that shareholder Hong Kong Yuanshi International Co., Ltd. plans to reduce its stake by up to 3.2004 million shares, accounting for 1% of the total share capital, due to personal funding needs [1] - Sunflower intends to acquire 100% equity of Xi Pu Materials and 40% equity of Zhejiang Beid Pharmaceutical through a combination of share issuance and cash payment, with stock resuming trading on September 22, 2025 [1][2] - Crown Zhong Ecology is planning a change in control, leading to a temporary suspension of its stock and convertible bonds due to significant uncertainties [2] Group 2 - China Oil Engineering's wholly-owned subsidiary signed a $513 million EPC contract for an LNG pipeline project in the UAE, covering approximately 180.5 kilometers of natural gas pipeline with a 36-month construction period [3] - Shanxi Fenjiu announced that shareholder Huachuang Xinrui (Hong Kong) Co., Ltd. plans to reduce its stake by up to 16.2006 million shares, representing no more than 1.33% of the total share capital [4] - Brother Technology's subsidiary received a drug registration certificate for Iopamidol injection, which is included in the national medical insurance catalog [5] Group 3 - Lin Yang Energy is expected to win a bid for a metering equipment project from the State Grid, with an estimated total bid amount of approximately 142 million yuan [6] - Huahai Chengke received approval from the China Securities Regulatory Commission for issuing shares and convertible bonds to purchase assets and raise no more than 800 million yuan in matching funds [8] - Jindi Co. signed a framework agreement to acquire controlling interest in Unico Precision, which specializes in manufacturing gears and automotive parts [10] Group 4 - Ruifeng High Materials announced that its major shareholder plans to reduce its stake by up to 2.4 million shares, accounting for 0.9584% of the total share capital [12] - Changliang Technology's director plans to reduce his stake by 1.05 million shares, representing 0.129% of the total share capital [14] - Zhongjing Food's director plans to reduce his stake by up to 150,000 shares, accounting for 0.10% of the total share capital [16] Group 5 - Haitai Technology announced that two shareholders plan to reduce their stakes by a total of up to 2.53% of the total share capital [18] - Zhenlei Technology's chairman is under detention but the company states that control has not changed and operations remain normal [20] - Huakang Co. plans to distribute a cash dividend of 0.2 yuan per share, totaling approximately 60.61 million yuan [19]

人民财讯9月21日电，兄弟科技（002562）9月21日公告，全资子公司浙江兄弟药业有限公司于近日收到 国家药品监督管理局核准签发的《药品注册证书》。药品名称为碘帕醇注射液，碘帕醇注射液主要用于 心血管造影、周围动脉造影及静脉造影、冠状动脉造影、脑血管造影、尿路造影、腰/胸及颈段脊髓造 影、关节造影等及CT增强检查，具有粘度低、安全性好等特点。 ...

Core Viewpoint - Brother Technology (002562) has received approval from the National Medical Products Administration for the iodine contrast agent injection, Iohexol, allowing for its official market launch in China, which enhances the company's competitiveness in the contrast agent sector [1] Group 1 - Brother Technology's wholly-owned subsidiary, Zhejiang Brother Pharmaceutical Co., Ltd., has obtained the drug registration certificate for Iohexol injection [1] - Iohexol injection is primarily used for various types of angiography and CT enhancement examinations, characterized by low viscosity and good safety [1] - The approval for Iohexol injection marks a significant step for Brother Pharmaceutical in commercializing this product and expanding its iodine contrast agent product line [1]

Core Viewpoint - Brother Technology (002562.SZ) announced that its wholly-owned subsidiary, Zhejiang Brother Pharmaceutical Co., Ltd., has received the drug registration certificate for Iohexol injection from the National Medical Products Administration, allowing for commercial sales in China [1] Group 1 - The Iohexol injection is primarily used for various types of imaging procedures, including cardiovascular, peripheral artery, venous, coronary, cerebral, urinary tract, spinal, and joint imaging, as well as CT enhancement [1] - The product is characterized by low viscosity and good safety, which are significant advantages in its application [1] - The approval for Iohexol injection marks a significant step for Brother Pharmaceutical in commercializing this product, enhancing its product line of iodine contrast agents and increasing its competitiveness in the contrast agent market [1]

Core Viewpoint - Brother Technology (002562.SZ) announced that its subsidiary, Brother Pharmaceutical, has recently received the Drug Registration Certificate issued by the National Medical Products Administration for Iopamidol Injection, which is primarily used for various types of angiography and CT enhancement examinations [1] Group 1 - The Drug Registration Certificate numbers are 2025S02892 and 2025S02893 [1] - Iopamidol Injection is utilized for cardiovascular angiography, peripheral artery angiography, venous angiography, coronary angiography, cerebrovascular angiography, urinary tract angiography, spinal cord angiography, and joint angiography [1] - The product is characterized by low viscosity and good safety [1]

兄弟科技9月21日公告，公司全资子公司浙江兄弟药业有限公司获得国家药品监督管理局核准签发的碘 帕醇注射液《药品注册证书》。碘帕醇注射液主要用于心血管造影、周围动脉造影及静脉造影、冠状动 脉造影、脑血管造影、尿路造影、腰/胸及颈段脊髓造影、关节造影等及CT增强检查，具有粘度低、安 全性好等特点。碘帕醇注射液已被纳入国家医保甲类目录，并已纳入第七批国家药品集中采购目录。 ...

Group 1 - Brother Technology's wholly-owned subsidiary, Zhejiang Brother Pharmaceutical Co., Ltd., has received the drug registration certificate for "Iohexol Injection" from the National Medical Products Administration [1] - As of January to June 2025, Brother Technology's revenue composition is 97.09% from fine chemicals and 2.91% from other segments [1] - The current market capitalization of Brother Technology is 7.8 billion yuan [1]

Core Viewpoint - Zhejiang Starry Pharmaceutical Co., Ltd. reported a steady growth in revenue and profit for the first half of 2025, driven by improved operational efficiency and a favorable market environment for iodine contrast agents [1][5]. Financial Performance - The company's operating income for the first half of 2025 was approximately CNY 1.40 billion, representing a 5.06% increase compared to the same period last year [2][5]. - Total profit reached approximately CNY 39.09 million, a significant increase of 41.30% year-on-year [2][5]. - Net profit attributable to shareholders was approximately CNY 29.14 million, up 27.24% from the previous year [2][5]. - The net cash flow from operating activities surged by 620.57% to approximately CNY 126.64 million, primarily due to reduced cash payments for goods and services [2][5]. Industry Overview - The company operates in the iodine contrast agent segment of the pharmaceutical manufacturing industry, which is experiencing steady global growth [3][5]. - The market for contrast agents is primarily dominated by original research products, with increasing opportunities for generic products, especially in emerging markets like China [3][5]. - The industry faces challenges such as capacity constraints and regulatory compliance, which are influencing production expansion strategies [3][5]. Business Operations - The company specializes in the research, production, and sales of non-ionic iodine contrast agents, with a comprehensive product line including iodinated contrast media and related intermediates [4][5]. - The operational model focuses on market demand, ensuring stable supply chains and optimizing production based on product profitability [5]. - The company has established long-term relationships with key suppliers, enhancing its ability to manage resource and cost fluctuations effectively [5]. Competitive Position - The company is recognized as one of the leading manufacturers of iodine contrast agents in China, with a strong market presence and competitive advantages in production capabilities [5]. - It has successfully participated in national procurement programs, achieving a high coverage rate and stable performance in fulfilling contracts [5]. - The company aims to expand its international market presence while maintaining a strong foothold in the domestic market, leveraging its integrated production capabilities [5].

Core Viewpoint - The article highlights the ongoing issues with the timely supply of drugs and medical devices following centralized procurement in various regions of China, indicating a significant number of products have not established delivery relationships post-selection, which raises concerns about the reliability of selected suppliers [1][9]. Group 1: Issues with Drug Supply - As of May 31, 2023, 443 drug specifications have not established timely delivery relationships after centralized procurement in Guangzhou, with nearly 70% of the 221 identified underperforming products having a delivery rate of 0 [9][10]. - The Hebei Provincial Medical Procurement Center has announced that certain companies will be rated as "generally" untrustworthy due to inadequate delivery services, including Suzhou Terui Pharmaceutical and Lizu Group, which are involved in multiple national procurement batches [2][5]. Group 2: Specific Products and Companies - Lizu Group's voriconazole injection was selected in the eighth batch of national procurement at a price of 29.19 yuan per unit, a significant drop from its previous market price of 700-800 yuan, reflecting a price reduction of over 90% [2]. - Northland Pharmaceutical's iohexol injection was selected in the seventh batch of national procurement at a price of 91.3 yuan per unit, being the only contrast agent selected in that batch [3]. Group 3: Regulatory Framework and Consequences - The Hebei Provincial Medical Procurement Center has established a credit evaluation system for pharmaceutical pricing and procurement, categorizing untrustworthy behavior into four levels: "general," "medium," "serious," and "particularly serious" [7]. - Companies identified as untrustworthy may face consequences such as written warnings, risk notifications on procurement platforms, and restrictions on the procurement qualifications of related drugs and materials [7]. Group 4: Broader Supply Issues - Beyond medical institutions, there are also reported supply shortages in designated pharmacies, with 422 drugs not supplied, affecting various products and involving 289 manufacturers [8].